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We previously showed that estradiol can have both defeminizing and feminizing effects on the 
developing mouse brain. Pre- and early postnatal estradiol defeminized the ability to show 
lordosis in adulthood, whereas prepubertal estradiol feminized this ability. Furthermore, we 
found that estradiol upregulates progesterone receptors (PR) during development, inducing both a 
male-and female-typical pattern of PR expression in the mouse hypothalamus. In the present 
study, we took advantage of a newly developed PR antagonist (ZK 137316) to determine whether 
PR contributes to either male- or female-typical sexual differentiation. Thus groups of male and 
female C57Bl/6j mice were treated with ZK 137316 or oil as control: males were treated 
neonatally (P0-P10), during the critical period for male sexual differentiation, and females were 
treated prepubertally (P15-P25), during the critical period for female sexual differentiation. In 
adulthood, mice were tested for sexual behavior. In males, some minor effects of neonatal ZK 
treatment on sexual behavior were observed: latencies to the first mount, intromission and 
ejaculation were decreased in neonatally ZK treated males; however, this effect disappeared by 
the second mating test. By contrast, female mice treated with ZK during the prepubertal period 
showed significantly less lordosis than OIL-treated females. Mate preferences were not affected 
in either males or females treated with ZK during development. Taken together, these results 
suggest a role for PR and thus perhaps progesterone in the development of lordosis behavior in 
female mice. By contrast, no obvious role for PR can be discerned in the development of male 


















The classic theory of mammalian brain and behavioral sexual differentiation holds that 
male-typical neural and behavioral characteristics develop under the influence of perinatal 
testosterone, whereas female-typical neural and behavioral characteristics develop in the absence 
of any hormonal secretions, i.e. by default. In rodents much evidence suggests that many, though 
not all, of the perinatal organizational actions of testosterone on the development of the male 
nervous system actually result from the cellular effects of estradiol formed via the local, neural 
aromatization of circulating testosterone (reviewed in Baum, 1979). Accordingly, it was proposed 
many years ago that the brain of the developing female rodent fetus is protected from the actions 
of maternal estradiol and/or from aromatized products of testosterone derived from male fetuses 
lying adjacent in the uterine horn by the relatively high affinity binding of estradiol by circulating 
alpha-fetoprotein (AFP) (McEwen et al., 1975). Indeed we showed that the capacity of AFP 
knockout (AFP-KO) female mice to display lordosis behavior in adulthood was severely 
attenuated and that this defect was reversed by prenatal treatment with an aromatase inhibiting 
drug (Bakker et al., 2006). These results provided important evidence that circulating AFP binds 
estradiol in female fetuses so as to protect their brains from the potential defeminizing actions of 
this hormone which otherwise normally occur in the male nervous system in response to estradiol 
synthesized from testosterone after it is taken up from the circulation. 
 The default organization of the female brain has however been challenged on several 
occasions (Toran-Allerand, 1984). Early behavioral studies showed that removal of the ovaries at 
birth actually reduced lordosis behavior in adult female rats, although these effects disappeared 
upon repeated testing (Dunlap et al., 1973; Gerall et al., 1973).  Furthermore, neonatal treatment 















behavior in female rats (Dohler et al., 1984), but the latter study was criticized because of the 
potential defeminizing effects of tamoxifen (Mathews et al., 1988). By using female mice 
carrying a targeted mutation of the aromatase gene (aromatase knockout or ArKO), we provided 
more robust evidence for a role of estradiol in the development of lordosis behavior (Bakker et 
al., 2002). Female ArKO mice showed significantly lower levels of lordosis behavior than wild 
type (WT) controls following adult ovariectomy and treatment with ovarian hormones.  However, 
administration of estradiol during a specific prepubertal period (i.e., postnatal days P15-25) 
significantly enhanced lordosis behavior in response to male mounts, almost up to levels 
observed in WT females (Brock et al., 2011). Interestingly, administration of estradiol during the 
neonatal period (P5-P15) completely defeminized lordosis behavior in WT females thereby 
emphasizing that the same hormone can have strongly opposing effects depending on when 
during development it is present or administered (Brock et al., 2011). It also suggests that there 
are two different developmental time windows for a male- versus a female-typical sexual 
differentiation of the mouse brain with male sexual differentiation proceeding pre- and early 
postnatally and female sexual differentiation predominantly postnatally, starting in the second 
week of postnatal life, which actually coincides with the onset of ovarian hormone secretion by 
the ovaries (Mannan and O'Shaughnessy, 1991).  
At present, the mechanisms, by which estradiol induces either a defeminization or 
feminization of the brain, are still unknown.  There is however robust evidence that estradiol up-
regulates the progesterone receptor (PR) through its receptor ERα (reviewed in Wagner, 2006). 
Interestingly, estradiol induces both the male- and female pattern in PR expression, i.e. higher PR 
expression in the male hypothalamus prenatally and early postnatally (E18-P10) in the 















ventromedial hypothalamus (P0-P20), whereas the female pattern in PR expression developed 
gradually throughout postnatal development, between P10 and P25 (Quadros and Wagner, 2008; 
Brock et al., 2010). These sex differences in PR expression over specific developmental periods 
might thus suggest a sex-specific role for PR and its substrate progesterone in male versus female 
brain sexual differentiation. At present, however, no conclusive evidence for a role of PR in brain 
sexual differentiation has been obtained. In addition, little is known about endogenous 
progesterone concentrations in the rodent brain during early development. Progesterone can 
either be locally produced or come from the circulation as it is secreted by the adrenal glands in 
both sexes (reviewed in Schumacher et al., 2014), and the ovaries starting around day 7 after birth 
in females (Mannan and O’Shaugnessy, 1991). Studies in male PRKO mice have provided 
opposite results, i.e. either an enhancement or an inhibition of male sexual behavior in adulthood 
(reviewed in Wagner, 2006). By contrast, in female PRKO mice, lordosis behavior was clearly 
disrupted but it could not be determined using the PRKO model whether it was due to a 
developmental defect since a functional PR is prerequisite for showing lordosis behavior (Lydon 
et al., 1995). Furthermore, studies in which either progesterone or its antagonist RU486 was 
administered to neonatal male rats, showed that male sexual behavior was disrupted by both 
treatments (reviewed in Wagner, 2006). Finally, in a more recent study (Forbes-Lorman et al., 
2014), the hypothesis of a sex-specific role for PR was determined directly by comparing male 
and female rats following treatment with RU486 during the neonatal period (P1-P7). Male sexual 
behavior was significantly increased in males perhaps due to increased expression of androgen 
receptors and thus increased sensitivity to androgens, but no effects were observed in females 
regarding lordosis behavior. The latter finding might not be surprising in light of our observation 
that the critical period for female sexual differentiation is later in life, as well as that PR 















Therefore, in the present study, we revisited the question of a potential sex-specific role for PR in 
male versus female brain sexual differentiation by taking advantage of a newly developed PR 
antagonist ZK137316, as well as that we treated male and female subjects during their respective 
critical periods, i.e. neonatally (P0-P10) for the males and prepubertally (P15-P25) for the 
females. RU486 has been criticized for its use as selective PR antagonist since it is known to 
interfere with glucocorticoid receptors, which is not the case for ZK137316 (Banaszak et al., 
2000; Fuhrmann et al., 2000; Sanchez-Criado et al., 2000; Xu et al., 2000; Slayden et al., 2001). 
Because ZK137316 was never used before in mice, a pilot study was conducted first to determine 
its potential to inhibit lordosis behavior as well as the expression of hypothalamic NPY receptors 
(YR1) in adult female mice, both variables being strongly dependent on a functional PR (Lydon 
et al., 1995; Xu et al., 2000). Next, we treated groups of male and female mice with ZK during 
development and determined its effects on sexual behavior. Finally, we determined whether 
treatment with ZK during development had long-lasting effects on steroid receptor expression, 
PR and ERα expression in females, and PR and AR expression in males, since Forbes-Lorman et 




All experiments were conducted in accordance with the guidelines established by the institutional 
animal care and use committee of the National Institutes of Health “Guide for the Care and Use 
of Research Animals, Eight Edition”, and were approved by the Ethical Committee for Animal 















were obtained from Charles River Breeding Laboratories (L’Arbresle, France) at the age of 8 
weeks. The male and female C57Bl/6j mice used for the developmental experiment were 
obtained from a local breeding colony at the animal facility of the University of Liège. All 
experimental animals were housed under a reversed light/dark cycle (12h:12h light/dark; 21.00h 
lights on and 9.00 lights off) with food and water ad libitum  
 
Ovariectomies and hormonal treatment: In adulthood, all experimental and stimulus females 
were bilaterally ovariectomized under general anaesthesia after an intraperitoneal injection (i.p.) 
of a mixture of ketamine (80mg/kg per mouse) and medetomidine (Domitor, Pfizer, 1 mg/kg per 
mouse). Mice received atipamezole (Antisedan, Pfizer, 4 mg/kg per mouse) subcutaneously (s.c.) 
at the end of the surgery in order to antagonize medetomidine-induced effects, thereby 
accelerating their recovery, as well as a s.c. injection of an analgesic (Temgesic, 0.05mg/kg per 
mouse). During ovariectomy, females received at the same time s.c. in the neck a 5-mm-long 
Silastic capsule (inner diameter: 1.57 mm; outer diameter: 2.41 mm; length: 5mm) containing 
crystalline 17β-estradiol (diluted 1:1 with cholesterol) to induce estrous levels of estradiol (for 
more details see Bakker et al., 2002). Females were allowed to recover for two weeks before the 
onset of the behavioral tests. All experimental and stimulus males were left gonadally intact. 
 
Behavioral tests 
Lordosis behavior: All lordosis tests were conducted in a Plexiglas aquarium (35cm long x 25cm 
high x 19cm wide) whose floor was covered with fresh sawdust. A sexually experienced male of 















Subsequently, 3 hours after receiving a progesterone injection (500µg), the female was placed in 
the aquarium and the lordosis responses of the female to the mounts of the stimulus male were 
recorded. Only when the female arched her back and adopted a rigid posture standing on all four 
paws, it was scored as lordosis, meaning that lordosis was not scored based on whether or not the 
male was able to achieve an intromission. We have noticed before that some males can achieve 
intromission even though the female is not fully receptive (no arching of the back). The test 
lasted until the female received 10 mounts or 15 min had elapsed. Tests were performed once a 
week during the dark phase of the light cycle (between 4 and 6 h after lights out). At the end of 
each test, a lordosis quotient (LQ) was calculated by dividing the number of lordosis responses 
displayed by the female subjects by the number of mounts received (x100).  
 
Male sexual behavior: All male sexual behavior tests were conducted in the same Plexiglas 
aquarium as described above. At the beginning of each test, the male was placed alone in the cage 
and allowed to adapt for 15 min. An estrous female (ovariectomized and brought into behavioral 
estrus) was then introduced into the cage and the latency to the first mount, intromission, and 
ejaculation, as well as the number of mounts, intromissions, and ejaculations, were recorded. The 
test lasted until ejaculation occurred or 30 min if no ejaculation was achieved. If a male never 
displayed a certain behavior within the 30 min test, the latency was scored as 1800 sec. 
 
Mate preference: To assess mate preferences, we used a box (60 x 13 x 30 cm) that was divided 
into three compartments by placing opaque partitions. Each compartment was thus 20cm in 
length. The partitions contained perforated holes at a height of 8cm to facilitate the diffusion of 
odors from the two side compartments to the middle compartment. Tests were performed during 















compartment box only once on the day before the behavioral experiments by placing them in the 
middle compartment for 10 min (with no stimulus animals placed in the two side compartments). 
On the day of testing, stimulus animals were placed in the two side compartments with their own 
bedding to make the stimulus as odorous as possible. The subject was then introduced into the 
middle compartment containing no sawdust, and was observed for 9 min. The time spent poking 
its nose through the holes of the partition or actively sniffing the bottom of the partition was 
recorded with a stopwatch.  
 
Non-reproductive behaviors: Because ZK137316 has not been used in mice before, we also 
determined whether it would affect other, non-reproductively-related behaviors. Therefore, we 
tested for general locomotor activity by using an open field as previously described (Dalla et al., 
2004; Taziaux et al., 2007). The number of line crossings (from one rectangle to another) was 
recorded during 10 min. We considered the line crossed when all four legs had passed. 
Furthermore, we also determined the state of anxiety by using an elevated plus maze as 
previously described (Dalla et al., 2004). At the beginning of the test, each mouse was placed in 
the center area and subsequently the time spent in the open and closed arms was recorded for 10 
min. In addition the number of entries into either the open or closed arms was registered. The 
mouse was considered to be in the open (or closed) arm when its four legs were no longer in the 
center area. These tests were conducted before mice were tested for their reproductive behavior. 
 
Determine whether ZK blocks lordosis behavior and Y1R expression 
ZK137316 (further referred to as “ZK”) was kindly provided by Bayer Pharmaceuticals. 















mice so far (Banaszak et al., 2000; Fuhrmann et al., 2000; Sanchez-Criado et al., 2000; Xu et al., 
2000; Slayden et al., 2001) . We selected two doses of ZK (6 and 9 mg/kg) based on previous 
studies in rats (Xu et al., 2000; Sanchez-Craido et al., 2000). For reasons of comparison, we also 
tested RU486 (Mifespristone; M8046, Sigma-Aldrich, France) at the dose of 12mg/kg adapted 
from previous rat studies (Xu et al., 2000; Gaytan et al., 2003; Carillo-Martinez et al., 2011).  
Adult C57Bl/6j female mice (8 weeks old) were ovariectomized and implanted with an estradiol 
capsule. Two weeks later, they were divided into 3 groups (n=7/8 per group). First, all females 
were tested for lordosis behavior during 3 consecutives tests (one test per week) to induce 
sufficient levels of lordosis 3h after receiving a s.c. injection with progesterone. Then, for the 
fourth test, females received either an injection of ZK at 6mg/kg (ZK6, n=8) or at 9mg/kg (ZK9, 
n=8) or RU486 at 12mg/kg (RU12, n=7) 2h before an injection with progesterone and thus 5h 
prior to the lordosis test. A fifth test was performed without ZK or RU486, but with progesterone, 
to determine whether lordosis behavior was restored to pre-treatment levels.   
Finally, to determine whether ZK would affect Y1r mRNA levels in the hypothalamus, the same 
females as used in the behavioral tests, were injected with either ZK at 6mg/kg (ZK6, n=4) or 9 
mg/kg (ZK9, n=4), RU486 at 12mg/kg (RU12, n=4) or OIL vehicle (OIL, n=8) 2h before 
receiving a progesterone injection and thus 5h before being euthanized by decapitation. This 
experiment was conducted one week after completing the behavioral tests. Brains were removed 
and the hypothalamus was dissected and then directly frozen in liquid nitrogen and stored at -
80°C until RNA extraction and RT-PCR. Hypothalamic tissues were homogenized with TRIzol
®
 
Reagents (1ml/100mg tissue) (15596-026, Life technologies). After sitting 5 min at room 
temperature (RT), chloroform was added (0.2mL/mL of TRIzol
®
 Reagent) and homogenates 















was transfered to a fresh tube and incubated with isopropanol (0.5mL/mL of TRI Reagent) for 10 
min at RT. Then, after centrigugation at 12.000g for 10 min at 4°C, the supernatant was removed 
and the RNA pellet washed by adding 0.5 mL of 70% ethanol. After vortex followed by 
centrifugation (7500 rpm for 5 min at 4°C), the RNA pellet was dried and resuspended in DEPC-
treated water for RNA quantification. RNA concentration and quality were determined using a 
Nanodrop ND-1000 spectrophotometer (Nyxor biotech, Paris). Two microgrammes of total RNA 
were saved for further use in the reverse transcription reaction, performed in a total volume of 10 
µl containing M-MLV Reverse Transcriptase (Promega), RNase Inhibitor (Promega) and oligo 
dT (Promega) mixed according to manufacturer’s instructions with each dNTP (Promega). Two 
microlitres of reverse transcriptase (in DEPC-treated water) was then used in a 25-µl PCR 
volume containing: 1X GoTaq® buffer (Promega), 0.2 mM of each dNTP (Invitrogen), 0.4µM of 
each primer: for Y1r (forward: 5’-CTGATGGACCACTGGGTCTT-3’; reverse: 5’-
CAGGAACGTCACCGAAGAAG-3’; Eurogentec) and for RPS11 (forward: 5’-
ACATGTCTGTGCACCTGTCC -3’; reverse: 5’-AGATTCCCCTGAGACCGTCT -3’; 
Eurogentec), and 1.25 U  of  GoTaq®  polymerase  (Promega). PCR products were visualised 
after standard electrophoresis in a 2.5% agarose gel. Semi-quantification of the intensity of RT-
PCR signals was carried out by a densitometric analysis on image from the electrophoresis gel 
with a computer-based image analysis system using the protocol for gel analysis 
(http://imagejdocu.tudor.lu/doku.php?id=video:analysis:gel_quantification_analysis) of NIH 
IMAGE, version 1.49 (Wayne Rasband, NIH, Bethesda, MD, USA). 
 















Pregnant females were checked daily for parturition towards the end of pregnancy. The day of 
birth was designated as postnatal day (P) 0. Based on the results of the pilot experiment, we 
selected the dose of 6mg/kg ZK for the developmental study. Males were treated between P0 and 
P10 and females between P15 and P25. For each developmental period, we conducted 3 
injections of ZK at 6mg/kg or OIL vehicle every 5 days. Thus, for the neonatal period, we 
injected s.c. ZK or OIL vehicle at P0, P5 and P10 and for the prepubertal period, we injected s.c. 
ZK or OIL vehicle at P15, P20 and P25. Treatments and developmental periods were not mixed 
between litters, thus one litter was either injected with ZK or oil neonatally or prepubertally. The 
total number of males injected were:  OIL (n=23 from 5 litters) and ZK (n=23 from 6 litters) and 
the total number of females injected were: OIL (n=15 from 4 litters) and ZK (n=17 from 4 
litters). Females used in the behavioral tests were ovariectomized in adulthood (P80) whereas 
males were left gonadally intact.  
 
Tissue processing for steroid receptor immunohistochemistry 
Perfusion Upon completion of all behavioral tests, male and female mice were anesthetized and 
perfused transcardially with saline followed immediately by 4% cold paraformaldehyde. Brains 
were removed and post-fixed in 4% paraformaldehyde for 2 hours. Brains were then 
cryoprotected in 30% sucrose/TBS solution during 72 h, frozen on dry ice and stored at -80°C 
until used. Brain sections were cut at 30µm thickness on a Leica CM3050S cryostat. Forebrains 
were cut coronally from the rostral telencephalon to the posterior hypothalamus. Sections were 
















Immunohistochemistry All incubations were carried out at room temperature and all washes were 
performed using Tris-buffered saline (TBS 0.05M) or Tris-buffered saline containing 0.1% 
Triton X-100 (TBST). Briefly, sections were rinsed and endogenous peroxidase activity was 
quenched by incubating the sections for 30 min with 3% hydrogen peroxide. Aspecific binding 
sites were then blocked by incubating sections for 30 min with 5% normal goat serum (NGS) 
(Dako Cytomation, Denmark). Sections were then incubated in TBST-5% NGS with either a 
rabbit polyclonal antibody against the progesterone receptor (1/2000, Dako; (Wagner et al., 
1998), a rabbit polyclonal antibody against ERα (1/20000, C1355, EDM Millipore; Moffatt et al., 
1998), both incubations overnight at 4°C, or a rabbit polyclonal antibody against the last 20 
amino acid N-terminal sequence of the human AR (1/250; sc-816 (N-20), Santa Cruz 
Biotechnology Inc., CA, USA; Forbes-Lorman et al, 2014) for 48h at 4°C. Then, sections were 
incubated for 1h in a goat anti-rabbit biotinylated antibody (1/1000 in TBST; Dako Cytomation, 
Denmark) followed by a 1h incubation in avidin-biotin complex (1/800, ABC, Vector 
Laboratory) and finally reacted for 3 min with 3,3’diaminobenzidine tetrahydrochloride (0.04% 
DAB and 0.012% H2O2). Sections were washed, dried overnight, left in xylene (Sigma) for 
10min and coverslipped using Eukit (Fluka, Steinheim, Germany). 
 
Data analysis The total amount of immunoreactivity (ir) for each receptor was analyzed as 
previously described (Brock et al., 2010; 2015) Briefly, one representative section was selected 
for several brain nuclei and was digitized using a video camera (CFW 1612C; Scion Corp., 
Frederick, MD, USA) attached to a microscope (MTV-3, x 20 objective; Olympus, Tokyo, 
Japan). Then, immunoreactivity was quantified with a computer-based image analysis system 















Bethesda, MD, USA). Digital images were made binary, and a manual threshold was used for 
discriminating the labeled material from the background. The total amount of PR-, ERα-, or AR-
ir was measured in one entire field and then determined by measuring the area (µm²) covered by 
‘thresholded’ pixels [i.e. those pixels with a grey level higher than a defined threshold density 
(specific immunoreactive staining)].  
 
Statistical analyses: All statistical analyses were performed using Statistica® 10.0. First, it was 
determined whether the data followed a normal distribution. If so, then data were analyzed using 
oneway or repeated measures ANOVA. When appropriate, all ANOVAs were followed by 
Fisher’s Least Significant difference (LSD) post hoc comparisons adapted for repeated-measures 
ANOVA. If not, then data were analyzed using Mann Whitney U tests. Regarding the pilot 
experiment on the ability of ZK to block lordosis behavior, we performed a t-test comparing the 
4
th
 test (i.e. injection of the PR antagonist) with the other tests (i.e. no PR antagonist). For the 
semi-quantification of Y1r mRNA level, we used the Kruskall-Wallis test. Regarding the 
developmental experiment, the lordosis data were analyzed using repeated measures ANOVA 
with treatment as independent variable and test as the repeated measure. The relative amount of 
PR-ir, ERα-ir and AR-ir was analyzed using oneway ANOVA for each brain region analyzed. 
Only significant (P < 0.05) effects detected by the ANOVAs and post hoc comparisons are 



















Determine the ability of ZK to decrease lordosis behavior and Y1R mRNA expression 
Lordosis behavior. As previously shown, lordosis behavior increased over repeated testing 
(Figure 1: tests 1-3). A single injection of ZK at 6mg/kg (Figure 1A), but not at 9mg/kg (Figure 
1B) significantly reduced lordosis behavior. By contrast, a single injection of RU486 did not 
significantly reduce lordosis behavior (Figure 1C). Thus when comparing lordosis quotients of 
test 4 with those of test 3, the reduction was only significant when females were treated with 6 
mg/kg of ZK (t=3.16, p=0.015, d=4.0767; figure 1A). Finally, lordosis behavior was completely 
restored in females previously treated with 6mg/kg of ZK when tested once more (test 5; t=3.07, 
p=0.01, d=4.0300; Figure 1A). An increase in lordosis behavior in the fifth test was also observed 
for females treated with 9mg/kg of ZK (Figure 1B) or with 12mg/kg RU486 (Figure 1C), but 
none of these reached statistical significance. 
Y1R mRNA expression. An overall effect of treatment was observed in Y1R mRNA expression 
(H(3,20)=11.65, p=0.008). Subsequently, post-hoc analysis revealed that treatment with ZK at 
6mg/kg significantly reduced Y1R messenger RNA levels in the hypothalamus of female mice 
(p=0.009, d=9.01) compared to OIL-treated female mice. Although Y1R mRNA levels seemed to 
be lower in females treated with ZK at 9mg/kg or RU486 at 12mg/kg compared to OIL, it was 
not statistically significant (ZK9: p= 0.61; RU486: p=0.26) (Figure 2).  
 

















Male sexual behavior Neonatal treatment with ZK had some minor effects on male sexual 
behavior, but only in the first mating test (Table 1). Thus, latencies to the first mount 
(F(1,43)=8.79, p=0.0049, d=4.2303), intromission (F(1,43)=4.22, p=0.046, d=2.9003) and ejaculation 
(F(1,43)=5.48, p=0.024, d=3.2834) were significantly shorter in neonatally ZK-treated males 
compared to OIL-treated males. By contrast, the number of mounts with and without pelvic 
thrusts, intromissions, and ejaculations did not differ between neonatally ZK-treated and OIL-
treated males in either of the 2 mating tests (Table 1). 
 
Mate preference ANOVA indicated a significant effect of neonatal ZK treatment (F(1, 84) = 
10.20  p=0.002, d=3.1216) as well as odor stimulus (F(1, 84) = 25.99 p<0.0001, d=3.1216), but no 
significant interaction (F(1, 84) = 0.1448  p= 0.7045), indicating that both ZK and OIL-treated 
males spent more time sniffing the side containing the estrous female over the side containing the 
male (Figure 3). Furthermore, neonatally ZK-treated males spent overall more time sniffing both 
sides of the three compartment box compared to OIL-treated males. 
 
Non-reproductive behaviors Neonatal treatment with ZK had no effect on general locomotion in 
an open field nor did it affect the time spent in the open versus the closed arms in the elevated 
plus maze (data not shown). 
 
PR and AR expression Neonatal treatment with ZK had no effect on PR expression in any of the 















terminalis (BST) (U=3.0, p=0.015, d=4.631) and a trend for a decrease in the medial preoptic 
area (mPOA) (F(1,10)=4.34, p=0.06, d=2.9458) in males treated neonatally with ZK compared to 
OIL-treated males (Tables 2 and 3).  
 
Females 
Lordosis behavior Prepubertal treatment with ZK significantly reduced lordosis behavior when 
tested in adulthood after priming with ovarian hormones (Figure 4A). Statistical analysis with 
repeated measures ANOVA indicated a significant effect of treatment (F(1,26)=8.17, p=0.008, 
d=0.24). Post hoc comparisons showed that lordosis behavior was particularly decreased in ZK-
treated female mice in tests 2 (p=0.049, d=2.2197), 5 (p=0.02, d=3.7726) and 6 (p=0.02, 




 test, post hoc comparisons detected only a trend (test 3: p= 0.07, 
d=2.2565; test 4: p=0.06, d=2.8939).  
 
Mate preference In contrast with lordosis behavior, mate preferences did not seem to be affected 
by prepubertal treatment with ZK. The ANOVA showed neither a significant effect of 
prepubertal treatment nor odor stimulus, indicating that neither OIL- nor ZK-treated females 
showed a clear mate preference (figure 4B).  
 
Non-reproductive behaviors Prepubertal treatment with ZK had no effect on general locomotiony 















more time in the closed arm (U=61.5, p=0.021, d=3.3411) and less time in the open arm (U=61.5, 
p=0.021, d=3.3411) of the elevated plus maze than oil-treated females (Figure 5 C).  
 
PR and ERα expression Blocking PR during prepubertal development had no effect on the 
relative amount of PR-ir or ERα-ir in any of the brain regions analyzed (Tables 2 and 4). 
 
Discussion 
In the present study we took advantage of a newly developed PR antagonist ZK137316 which 
does not to interfere with glucocorticoid receptors, to revisit the question of whether PR plays a 
sex-specific role in brain sexual differentiation. We found little evidence for such a role for PR in 
male sexual differentiation since no strong, long-lasting, effects on male sexual behavior were 
observed in males treated neonatally with ZK. By contrast, females treated with ZK during the 
prepubertal period showed significantly less lordosis behavior than OIL-treated controls. These 
results suggest a potential role for PR and consequently progesterone in brain feminization, at 
least for the development of lordosis behavior. 
 
PR and lordosis behavior. Prepubertal treatment with the PR antagonist ZK137316 significantly 
decreased lordosis behavior in adult female mice primed with ovarian hormones. This decrease in 
lordosis behavior was not due to any long-lasting effects of ZK on the expression of PR or ERα, 
both receptors known to be crucial for the expression of lordosis behavior in adulthood (Laudau 















suggests some organizational role for PR and by consequence progesterone in lordosis behavior. 
Interestingly we observed reduced brain progesterone levels in female ArKO mice at P15 
(unpublished data). If indeed progesterone is required for the development of lordosis behavior, a 
next logical step would be to inject progesterone in ArKO mice during the prepubertal period to 
determine whether it will restore lordosis behavior in these mice. 
However, some caution is warranted in interpreting the results of the present study. In contrast 
with earlier studies on lordosis behavior (Bakker et al., 2002; 2006; Brock et al., 2011), we did 
not observe the typical increase in lordosis behavior in the OIL-treated females during repeated 
testing. Actually, quite surprisingly, lordosis quotients were quite similar between OIL- and ZK-
treated females in the first test, i.e. around 30%. Then in the following tests, lordosis increased 
slightly in the OIL-treated females (but not significantly) whereas it decreased in prepubertally 
ZK-treated females. An alternative interpretation could thus be that testing for lordosis behavior, 
i.e. interacting with a male, might have induced some aversive effects in ZK-treated females. 
However, females were tested for mate preferences after the final lordosis test, and ZK-treated 
females showed like OIL-treated females a male-directed preference suggesting that sexual 
motivation was not affected by prepubertal ZK treatment.  Finally, another explanation could be 
that peripubertal ZK treatment has affected cognitive abilities. Rat studies have shown that PR is 
expressed transiently in the developing cortex and progesterone might thus play a role in cortical 
development (Quadros et al., 2007). Although a recent study (Willing and Wagner, 2014) using 
PRKO mice suggested some role for PR in maturation of cortical connectivity and sensorimotor 
integration, clearly more research is needed to elucidate the role of PR in cortical development. 















prepubertal treatment with ZK remains that PR and thus progesterone are needed for the 
development of lordosis behavior.  
 
PR and male sexual behavior The observation that PR expression is much higher in the male 
compared to the female hypothalamus during pre- and early postnatal development suggest a 
specific role for PR in the development of the male brain (Quadros and Wagner, 2008; Brock et 
al., 2010). Several studies have addressed this question by either using PRKO mice or injecting 
the well-known PR antagonist RU486. None of these studies have actually provided consistent 
results since either a decrease, no effect, or an increase in adult male sexual behavior was 
observed (reviewed in Wagner, 2006). One possible explanation could be that PR actually affects 
AR expression and perhaps thus AR-sensitive behaviors such as male copulatory behavior. For 
instance AR expression as well as male sexual behavior was increased in male PRKO mice 
(Schneider et al., 2005). In addition, in the recent study by Forbes-Lorman et al (2014), it was 
shown that blocking PR temporarily during neonatal development by injecting RU486 increased 
AR expression in several brain areas important for sexual behavior (i.e. BST, mPOA, 
dorsomedial VMH, medial amygdala) as well as male sexual behavior, the number of mounts and 
intromissions as well as shorter latencies to mount the female. In the present study, we observed 
shorter latencies to mount, intromit, and ejaculate in neonatally ZK-treated males compared to 
OIL-treated males, but no effects on the number of mounts, intromissions, or ejaculations. In 
addition, these effects were not long-lasting since there were no differences between the groups 
in the second mating test. The behavioral protocol used in our study is quite different from the 
one in the study by Forbes-Lorman and colleagues, in which males were gonadectomized, 















third test were provided, in addition to studying different species, mice versus rats. Furthermore, 
we found actually opposite effects regarding AR expression, i.e. a decrease in AR-ir in the BST 
and mPOA. Importantly we studied AR expression in gonadally intact male mice so it is possible 
that decreased AR expression actually reflects decreased testosterone levels in neonatally ZK-
treated males. Since we found no deficits in male sexual behavior after neonatal ZK treatment, 
we did not pursue this study any further by castrating the males, treating them with testosterone 
and then re-test for male sexual behavior. Furthermore, neonatal ZK treatment had no effect on 
mate preference and thus sexual motivation, since they showed a clear preference for the estrous 
female over the sexually active male as did OIL-treated males. They spent more time sniffing 
both stimuli however, suggesting some hyperactivity in these males, but this was not confirmed 
in the open field test. Taken together, the question of why there is such a sex difference in PR 
expression during pre- and neonatal development remains yet to be answered. However, it should 
be kept in mind that even there is no strong evidence for PR or progesterone in male sexual 
differentiation, the male brain will be responsive to exogenous progesterone, such as progestins 
prescribed to women in late pregnancy to prevent premature delivery. 
 
Increased anxiety in females. Locomotion measured in either an open field or elevated plus maze 
was not affected by prepubertal treatment with ZK. Nevertheless, prepubertally ZK-treated 
females spent more time in the closed than in the open arms of the EPM suggesting an increased 
state of anxiety. This result suggests that blocking progesterone receptors during the prepubertal 
period might have affected the neural circuits controlling stress responses in female mice. Indeed, 
numerous studies have shown a role of progesterone and/or its metabolites in stress and 















as sensitivity to stress have been reported to fluctuate over the estrous cycle, suggesting a specific 
role of ovarian hormones in stress, anxiety-like behavior and mood disorders (for review, see ter 
Horst et al., 2012). Finally, estradiol and progesterone might induce anxiety-like behavior since 
ovariectomized WT mice as well as ERKO/PRKO mice showed enhanced anxiety-like behavior 
(reviewed in Blaustein and Ismail, 2013).  In the present study, PR and ERα expression was not 
affected by prepubertal ZK treatment thus the increase of anxiety-like behavior observed is most 
likely not due to any alteration in PR and ERα signaling. However, the possibility cannot be ruled 
out that other sex steroid receptors such as ERβ (Imwalle et al., 2005) or other neuronal targets 
important in anxiety were affected by prepubertal treatment with ZK. It remains however rather 
unlikely that the decrease in lordosis behavior was actually caused by increased anxiety since no 
specific stress responses were observed when ZK-treated females were tested for their lordosis 
behavior. There was no excessive running away from the male or any attempts to jump out of the 
testing apparatus. In addition, mate preferences were not affected: ZK-treated females showed 
like OIL-treated females a strong preference for the odors of a male.  
 
In conclusion, the present study showed for the first time a potential role of PR in the 
development of female sexual behavior. However, more research is needed to further elucidate 
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Legends to the Figures 
 
Figure 1: Dose effect of ZK137316 on lordosis behavior in adult female mice. Following 3 pre-
tests, 5h before the 4
th
 test, adult female mice were injected s.c. with either (A) 6 mg/kg of ZK 
(ZK 6) or (B) 9 mg/kg (ZK 9) or (C)12 mg/kg of RU486 (RU 12). Then, a fifth test was 
performed with just estradiol and progesterone. Values are presented as means ± SEM. *p<0.05.  
 
Figure 2: Dose effect of ZK137316 on Y1r mRNA hypothalamic levels in adult female mice. 
Adult females mice were injected either with OIL (n=8) or ZK at 6mg/kg (ZK 6) or ZK at 
9mg/kg (ZK 9) or RU486 at 12mg/kg (RU 12) then killed 2h later and the hypothalamic level of 















Photomicrographs representing the Y1r and RPS11 mRNA electrophoresis gel. (B) Histogram 
showing the average of Y1r mRNA/ RPS11 mRNA ratio intensity for each group. Values are 
means ± SEM. * p<0.05 
 
Figure 3: Mate preference of adult male mice treated with ZK137316 during the neonatal period. 
Time spent sniffing estrous female versus intact male volatile odors in the 3CB. Values are 
presented as means ± SEM. **p<0.01, ***p<0.001. 
 
Figure 4: Sexual behavior of adult female mice treated with ZK137316 during the prepubertal 
period. (A) Lordosis quotients; (B) Time spent sniffing estrous female versus intact male volatile 
odors in the 3CB. Values are presented as means ± SEM. #p<0.07, *p<0.05 
 
Figure 5: Locomotion and anxiety in adult female mice treated with ZK137316 during the 
prepubertal period. (A) Mean number of line crossings in the open field (OF). (B) Mean number 
of entries in the elevated-plus maze (EPM). (C) Mean number of time spent in either the open or 



















Table 1: Male sexual behavior after neonatal treatment with ZK or OIL. Mean number of mounts (MTS), intromissions (INTS) and ejaculations 
(EJAC) displayed during the 30-min test. Latencies are expressed in seconds; ML, Mount latency; IL, intromission latency; EL, ejaculation 
latency. **p<0.01, *p<0.05 
 
  
  Numbers Latencies (s) 
 Treatment MTS INTS EJAC ML IL EL 
Test 1 OIL (n=23) 9.65 ± 2.54 107.78 ± 37.85 0.26 ± 0.09 787.17 ± 149.05  1392.26 ± 121.21 1717.30 ± 36.19 
ZK (n=22) 11.68 ± 1.89 114.77 ± 25.57 0.09 ± 0.10 304.5 ±  58.16 ** 990.77 ± 157.42 * 1479.86 ± 96.62* 
Test 2 OIL (n=23) 12.87 ± 1.96 196.26 ± 38.08 0.69 ± 0.09 432.87 ± 120.54 820 ± 157.32 1290.43± 100.75 















Table 2: Relative amount of PR-ir in different hypothalamic regions in female and male mice treated 
with ZK or OIL during the prepubertal (females) or neonatal (males) period. mPOA, medial preoptic 
area;  AVPV, anteroventral periventricular area; ARC, arcuate nucleus; VMHvl, ventrolateral 
ventromedial hypothalamus.  
 
Table 3: Relative amount of AR-ir in different hypothalamic regions in male mice treated with ZK or 
OIL during neonatal development. mPOA,medial preoptic area;  BST, bed nucleus of stria terminalis; 
LS, lateral septum; ARC, arcuate nucleus; DMH, dorsomedian hypothalamus, VMHvl, ventrolateral 
ventromedial hypothalamus; VMHdm, dorsomedial ventromedial hypothalamus; MeA, Medial Amygdala  








Table 4: Relative amount of ERα-ir in different hypothalamic regions in female mice treated with ZK 
or OIL during prepubertal development. mPOA, medial preoptic area;  AVPV, anteroventral 
periventricular area; ARC, arcuate nucleus; VMHvl, ventrolateral ventromedial hypothalamus. # p<0.07; * 






  PR-ir in FEMALES treated 
PREPUBERTALLY 
PR-ir in MALES treated NEONATALLY 
 OIL (n=5) ZK (n=5) OIL (n=6) ZK (n=6) 
mPOA 30337.6 ± 2215.6 36633.8 ± 2880.7 5428.17 ± 1371.65 3301.83 ± 1343.24 
AVPV 16371.2 ± 2659 23539.8 ± 7267.3 3457 ± 565 4216.33 ± 2208.29 
ARC 18029.6 ± 3899.2 14717.6 ± 2756.9 1700.2 ± 700.23 1222.33 ± 474.29 
VMHvl 25514.4 ± 5595.5 21181 ± 9057.3 3203.33 ± 1266.71 2581.17 ± 1458.04 
 AR-ir 
 OIL (n=6) ZK (n=6) 
mPOA 10127.67 ± 2784.48 3784.17 ± 1233.27 # 
BST 328.5 ± 100.32 0 ± 0 * 
LSV 170.33 ± 121.12 287 ± 138.48 
ARC 4103.67 ± 1319.25 2674.83 ± 1616.27 
DMH 165.83 ± 95.68 196.5 ± 156.20 
VMHvl 2449.67 ± 1095.46 3856.17 ± 2889.67 
VMHdm 491.67 ± 350.64 8.33 ± 8.33 
MeA 1316.17 ± 875.70 2023.5 ± 952.22 
 ERα-ir 
 OIL (n=5) ZK (n=5) 
mPOA 22819.6 ± 7606.1 13026.2 ± 5315.1 
AVPV 28531.8 ± 7625.7 20494.8 ± 4315.9 
ARC 20071.2 ± 2429 22207 ± 4130 










































































































- Prepubertal treatment with the PR antagonist ZK137316 affected lordosis behavior in 
female mice 
- Potential role for progesterone in the sexual differentiation of the female brain 
- Neonatal treatment with the PR antagonist ZK137316 had only minor effects on male 
sexual behavior 
- No clear role for progesterone or PR in male sexual differentiation 
